	US 12,421,214 B2
	Solid state forms of aprocitentan and process for preparation thereof
Petar Bibulić, Zagreb (HR); and Sanja Matečić Mušanić, Zagreb (HR)
Assigned to ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
Appl. No. 17/922,007
Filed by ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
PCT Filed May 21, 2021, PCT No. PCT/US2021/033525 § 371(c)(1), (2) Date Oct. 28, 2022, PCT Pub. No. WO2021/237004, PCT Pub. Date Nov. 25, 2021.
Claims priority of provisional application 63/028,159, filed on May 21, 2020.
Prior Publication US 2023/0167090 A1, Jun. 1, 2023
Int. Cl. C07D 403/12 (2006.01)

CPC C07D 403/12 (2013.01) [C07B 2200/13 (2013.01)]

15 Claims

1. A crystalline Form T12 of Aprocitentan, which is characterized by data selected from one or more of the following:

i) an XRPD pattern having peaks at 10.1, 13.3, 24.5, 26.7 and 28.5 degrees-2-theta±0.2 degrees 2-theta;

ii) an XRPD pattern as depicted in FIG. 6 or FIG. 8;

iii) a solid state ¹³C-NMR spectrum with peaks at 165.9, 162.0, 131.6, 128.9 and 103.7 ppm±0.2 ppm;

iv) a solid state ¹³C-NMR spectrum following chemical shift absolute differences from a peak at 65.3 ppm±2 ppm of 100.6, 96.7, 66.3, 63.6 and 38.4 ppm±0.1 ppm;

v) a solid state ¹³C NMR spectrum having chemical shift difference from a peak at 165.9 ppm±1 ppm of 100.6 ppm±0.1 ppm;

vi) a solid state ¹³C-NMR spectrum substantially as depicted in FIG. 10; or

combinations of (i)-(vi).